All Search Results
News Releases
Apr 01, 2026, 09:00 ET Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
presented data from the multiple ascending dose (MAD) cohorts of the Phase 1 trial evaluating BBT001 in healthy volunteers at the 2026 American Academy of Dermatology Annual Meeting (AAD 2026) in Denver, Colorado. The AAD 2026 clinical poster of BBT001 titled, "Safety, Tolerability, Pharmacokinetics,
More news about: Bambusa Therapeutics, Inc.
Mar 30, 2026, 08:00 ET Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
March 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in our aesthetics portfolio and insights on the aesthetic
More news about: AbbVie
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
with at least one additional weight-related comorbid condition. These results were presented in a late-breaking presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting and simultaneously published in Arthritis & Rheumatology. At the primary endpoint of 36 weeks, treatment
More news about: Eli Lilly and Company
Mar 28, 2026, 12:36 ET Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
March 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.
More news about: Nektar Therapeutics
Mar 28, 2026, 10:00 ET ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
More news about: Johnson & Johnson
